rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ABCL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      AbCellera at UBS Global Biopharma Conference 2026: phase ii data lifts outlook
      Nov 17Investing.comABCLUBS
      AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment
      Nov 16Yahoo FinanceABCL
      SoftBank exits Satellogic, trims stakes in Nu Holdings, VTEX, Ethos, AbCellera in Q3

      SoftBank's Q3 13F shows it exited Satellogic and cut Nu Holdings to 16.8 million shares from 17.8 million, with no new positions.

      Nov 16Seeking AlphaABCLSATLVTEX
      AbCellera at Jefferies Global Healthcare Conference: hot-flash drug takes center stage
      Nov 16Investing.comABCLJEF
      Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
      Nov 12Yahoo FinanceABCL
      AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results
      Nov 12Yahoo FinanceABCL
      StoneX raises AbCellera Biologics stock price target to $15
      Nov 11Investing.comABCL
      AbCellera at Stifel 2026 Healthcare Conference: hot flash drug shines
      Nov 11Investing.comABCLSF
      AbCellera Biologics Inc (ABCL) (Q3 2026) Earnings Call Highlights: Breakthrough Hot Flash Data ...
      Nov 10Yahoo FinanceABCL
      What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call
      Nov 10Yahoo FinanceABCL
      AbCellera Q3 2026 slides: ABCL635 data sets new VMS efficacy bar
      Nov 10Investing.comABCL
      Earnings call transcript: AbCellera beats Q3 2026 estimates as ABCL635 lifts shares
      Nov 9Investing.comABCL
      AbCellera Biologics Q3 2026 Earnings Call Transcript
      Nov 9BenzingaABCL
      AbCellera Reports Q3 2026 Business Results
      Nov 9Yahoo FinanceABCL
      Abcellera Biologics earnings on deck as ABCL635 takes spotlight
      Nov 9Investing.comABCL
      AbCellera (ABCL) Stock May Look Fully Priced On Book Value
      Nov 6Yahoo FinanceABCL
      AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026
      Nov 5Yahoo FinanceABCL
      Jefferies & Co Initiates Coverage on AbCellera Biologics With Buy Rating, $21 Price Target
      Oct 30Yahoo FinanceABCL
      Jefferies initiates AbCellera stock coverage with buy rating
      Oct 30Investing.comABCL
      AbCellera Has Promising Menopause Data But Much Of The Opportunity Is Priced In (ABCL)
      Oct 22Seeking AlphaABCL
      AbCellera Biologics' ABCL635 Seen With Best-in-Class Potential in Menopause, UBS Says
      Oct 12Yahoo FinanceABCL
      UBS Initiates AbCellera Biologics at Buy With $18 Price Target
      Oct 12Yahoo FinanceABCL
      UBS initiates AbCellera stock with buy rating on menopause drug potential
      Oct 12Investing.comABCL
      AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws Focus
      Oct 9Yahoo FinanceABCL
      AbCellera to Present Phase 1/2 ABCL635 Data at Menopause Society Meeting
      Oct 9Yahoo FinanceABCL
      AbCellera to present phase 1/2 data on menopause drug candidate
      Oct 8Investing.comABCL
      AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

      Business Wire Press Release.

      Oct 1The Globe and MailABCL
      JPMorgan initiates AbCellera stock coverage with overweight rating
      Sep 29Investing.comABCL
      Why is Abcellera Biologics stock climbing today?
      Sep 29Investing.comABCL
      JPMorgan Initiates AbCellera Biologics at Overweight With $17 Price Target

      AbCellera Biologics (ABCL) has an average rating of buy and mean price target of $16.70, according t

      Sep 29Yahoo FinanceABCL
      Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
      Sep 29Yahoo FinanceABCLIOVA
      Abcellera Biologics stock hits 52-week high at 13.23 USD
      Sep 28Investing.comABCL
      Goldman Sachs resumes AbCellera stock coverage with neutral rating
      Sep 24Investing.comABCL
      ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

      AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

      Sep 22Yahoo FinanceABCL
      AbCellera and Recursion Pharmaceuticals: two AI-drug stocks, two different stories
      Sep 18Investing.comABCL
      Abcellera Biologics stock hits 52-week high at 12.58 USD
      Sep 17Investing.comABCL
      AbCellera to present phase 2 data on menopause treatment drug
      Sep 16Investing.comABCL
      AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

      VANCOUVER, British Columbia, September 16, 2026--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

      Sep 16Yahoo FinanceABCL
      AbCellera at Cantor healthcare conference: nk3r drug boosts hopes
      Sep 10Investing.comABCL
      AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
      Sep 2Yahoo FinanceABCL
      What'sGoing On With AbCellera Biologics Stock On Tuesday?
      Aug 25BenzingaABCLJAZZ
      Abcellera Biologics stock hits 52-week high at 12.15 USD
      Aug 25Investing.comABCL

      This is the newest page. Registered accounts read further back.